Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NH160030
- Development stage
- Unknown
- Lead developer
- Jiangsu Nhwa Pharmaceutical
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
NH160030 is a novel small molecule analgesic candidate developed by Jiangsu Enhua Pharmaceutical. It is designed as a bifunctional ligand that acts as a mu-opioid receptor (MOR) agonist and a delta-opioid receptor (DOR) antagonist. This pharmacological profile aims to provide potent pain relief for chronic and cancer-related pain while minimizing the development of opioid tolerance and physical dependence, which are significant limitations of traditional pure MOR agonists like morphine. The drug is currently undergoing early-phase clinical evaluation in China to assess its safety, tolerability, and pharmacokinetic profile.
02
Targets
DOR (Opioid Receptor Delta 1)MOR (Mu opioid receptor)
Beyond the preview
Go deeper on NH160030.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NH160030.